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ABSTRACT: Orally administered Ag2S quantum dots (QDs) rapidly
cross the small intestine and are taken up by the liver. Metformin and
nicotinamide mononucleotide (NMN) target metabolic and aging
processes within the liver. This study examined the pharmacology and
toxicology of QD-based nanomedicines as carriers of metformin and
NMN in young and old mice, determining if their therapeutic potency
and reduced effects associated with aging could be improved.
Pharmacokinetic studies demonstrated that QD-conjugated metfor-
min and NMN have greater bioavailability, with selective accumu-
lation in the liver following oral administration compared to
unconjugated formulations. Pharmacodynamic data showed that the
QD-conjugated medicines had increased physiological, metabolic, and
cellular potency compared to unconjugated formulations (25× metformin; 100× NMN) and highlighted a shift in the peak
induction of, and greater metabolic response to, glucose tolerance testing. Two weeks of treatment with low-dose QD-NMN
(0.8 mg/kg/day) improved glucose tolerance tests in young (3 months) mice, whereas old (18 and 24 months) mice
demonstrated improved fasting and fed insulin levels and insulin resistance. High-dose unconjugated NMN (80 mg/kg/day)
demonstrated improvements in young mice but not in old mice. After 100 days of QD (320 μg/kg/day) treatment, there was
no evidence of cellular necrosis, fibrosis, inflammation, or accumulation. Ag2S QD nanomedicines improved the
pharmacokinetic and pharmacodynamic properties of metformin and NMN by increasing their therapeutic potency,
bypassing classical cellular uptake pathways, and demonstrated efficacy when drug alone was ineffective in aging mice.
KEYWORDS: pharmaceutical, drug development, nanocrystals, liver, pharmacokinetics, pharmacodynamics
Quantum dots (QDs) are multifunctional nanocrystalswith bioimaging, detection, and drug deliveryapplications.1,2 The ideal nanomaterial transporters
should have minimal effects on biological systems and be
removed and/or eliminated after drug delivery.3,4 One
limitation of QDs is that they can accumulate in the liver or
be phagocytosed by immune cells, leading to prolonged
exposure and potential toxicity.5 Recent progress toward
reducing toxicity includes specific biomimicry coating and the
use of nontoxic materials such as silver.6
The avid uptake and clearance of nanomedicines by the liver is
an obstacle for systemic therapies and therapies targeting other
organs, but this is an advantage for therapies targeting the liver
itself.7,8 Such pharmacotherapies include those targeting a range
of age-related and metabolic conditions.9 We previously
developed a QD nanocarrier that enhances oral bioavailability
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and hepatoselectivity. These 7 nmAg2S QDs rapidly accumulate
in the liver within 0.5 h of oral administration and are cleared
within 24−72 h, with the window between open to therapeutic
drug delivery to hepatocytes.10 We further demonstrated that
the rapid absorption across the small intestine was via clathrin-
mediated endocytosis and micropinocytosis.10 This previous
study showed that QD-mediated transport of metformin
increased its bioavailability in the liver; we therefore sought to
comprehensively examine the role of QDs as therapeutic drug
carriers to the liver.
The liver plays a critical role in regulating the metabolic
responses to nutrition. The canonical nutrient sensing pathways
Figure 1. Conjugation and characterization of Ag2S quantum dots (QDs) with metformin and nicotinamide mononucleotide (NMN). (A)
Water-soluble QDs with a hydrophilic external layer of carboxylic acid molecules on their surface (as shown using Fourier transform infrared
(FTIR) microscopy spectral analysis) are conjugated with metformin or NMN using EDC/NHS chemical coupling. Repeat FTIR spectra
analysis demonstrates an external layer of drug conjugate on these QDs. (B) QDs (gray) with/without drug attachment (QD-metformin (red)
and QD-NMN (blue)) demonstrated similar sizing when dried for visualization under transmission electron microscopy. Examination in
solution showed drug attachment increases the hydrodynamic diameter (C) and shifts zeta-potential toward 0 (D). The loading efficiency was
measured using a low (E) and high (F) concentration (concn) of QDs. The amount of drug retained following conjugation and 24 h at pH 7
under dialysis was 100%when a greater ratio of QDs to drug was used. When greater concentration of drug compared to QDs was used, loading
efficiency shifted toward 10%. A maximal drug attachment ratio was observed for metformin (90 mM/1 mM) and NMN (150 mM/1 mM) (G).
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involved in these responses are AMPK, sirtuin/NAD+, mTOR,
and insulin signaling pathways.9 As well as being involved with
metabolic responses such as insulin/glucose homeostasis, these
nutrient sensing pathways are disrupted with aging,11 and
medicines that target these pathways influence aging biology.9
For example, metformin, an extensively prescribed drug for type
II diabetes mellitus, also increases lifespan in animal models via
phosphorylation of AMPK.12 NAD+ is a cofactor for sirtuins and
supplementation with a precursor of NAD+,13 nicotinamide
mononucleotide (NMN), delays aging in mice14 and is also
effective in the treatment of diet- and age-induced diabetes.15
We previously reported the effects of metformin and NMN on
liver sinusoidal endothelial cells (LSECs) and the impact of
aging on the responses.16,17 In vitro, QD-metformin was taken
up by endocytosis rather than by its usual transporter, OCT1,
and had greater impact on AMPK activation than metformin
alone.10
Here, we comprehensively evaluate and provide the frame-
work for nanopharmaceutical evaluation. We examined
hepatoselective, orally administered QD-metformin and QD-
NMN formulations to determine (i) their pharmacokinetic and
pharmacodynamic properties, in particular, their effects on
glucose/insulin metabolism in vitro and in vivo and the cellular
pathways involved; (ii) the effects of old age on the physiological
responses to these nanomedicines and drug agents alone; and
(iii) the development of any toxicity following long-term
administration of QDs. We show that QD-metformin and QD-
NMN have dramatically increased hepatic bioavailability and
100- to 1000-fold improvements in metabolic effects compared
to drug alone. This potent effect is due to QD mediated
Figure 2. Pharmacokinetic and biodistribution data of (3H)QDs (gray), (14C)metformin (black), and QD-(14C)metformin (red) following oral
administration. Following ingestion, QDs, metformin, and QD-metformin accumulate in various organs. (A) Metformin uptake peaks in the
liver 8 h after administration; attachment to QDs leads to an earlier peak at 2 h. After 8 h, QDs show faster liver clearance than the attached
metformin, indicating detachment of drug from QDs. Over a 24 h period, a greater concentration of metformin is in the liver when it is
conjugated to QDs, as shown by the greater area under the curve (AUC). (B) Persistence in the small intestinal lumen is reduced when
metformin is attached to QDs; without attachment, 50% of metformin is localized to the intestine after 8 h compared to 25% of QD-metformin;
this contributes to a greater AUC for metformin compared to that for QD-metformin. (C) Similar fecal clearance of metformin and QD-
metformin was observed. (D) Blood concentration of metformin andQD-metformin demonstrated similar shifts; attachment toQDs allows for
faster passage into blood; concentration is reduced by 8 h followed by re-entry into the blood. Comparison toQD clearance from blood suggests
detachment of metformin from QDs similar to that observed in liver. (E) Kidney and (F) spleen demonstrate small accumulations of drug and
QDs. Following 24 h, less than 5% of materials remain in these organs with no differences in AUC between QD or metformin alone. Data show
mean ± SD (n = 3 per group, compared with Kruskal−Wallis test and post-hoc Dunn’s method; α = 0.05).
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improved pharmacodynamics, bypassing classical cellular uptake
pathways and absorption. This is most evident in old mice that
show improved insulin/glucose metabolism following 2 weeks
of QD-NMN treatment but did not respond to NMN treatment
alone. Finally, we observed no toxicity following 100 days of oral
QD administration.
RESULTS AND DISCUSSION
Synthesis and Characterization of Drug Loading on
Ag2S QDs. The synthesis and phase transfer of these QDs was
previously reported.10 The conjugation of metformin and NMN
to the QDs was performed using a two-step chemical
conjugation reaction. The first step involves EDC conjugation
to carboxylic groups on the QDs. The second step uses an NHS
catalyst for the formation of an amide bridge between these
carboxylic acid groups and the primary amine group on
metformin or NMN (Figure 1A).
Fourier transform infrared (FTIR) spectra demonstrated the
change in surface topology from carboxylic groups to a chemical
layer of metformin or NMN on the QDs (Figure 1A). The QDs
retained their solubility index in water to an upper threshold of
500 μg/mL; greater than this promoted aggregation. The
polydispersity index (PDI) was QD = 0.271 ± 0.025, QD-
metformin = 0.236 ± 0.038, QD-NMN = 0.231 ± 0.049
(Supplementary Figure 1). The QD-drug complex maintained
its 7 nm diameter (Figure 1B), with an increased hydrodynamic
diameter and right shifted (toward 0) zeta-potential with drug
attached (Figure 1C,D and Supplementary Figure 1). The
increase in hydrodynamic diameter was relative to the size of the
drug molecule attached: QD-metformin had a 25% increase,
while QD-NMN had a 75% increase in hydrodynamic diameter
compared to that with QD alone. The increase in zeta-potential
was related to the addition of positive charges from metformin
and NMN.
The loading efficiency of the drugs was limited by the
concentration of QDs which in turn limited the surface area for
drug attachment. When the ratio of QD/drug was 100:1, the
amount of drug retained on the surface of QDs after 24 h under
dialysis approached 100%. When the ratio was 1:1, 80% of the
drug was retained. Finally, when the ratio was 1:100, only 10% of
the drug retained on the surface of the QDs (Figure 1E,F). The
upper limits for attachment of metformin and NMN to QDs
were 90 and 150 mM, respectively, per 1 mMQDs (Figure 1G).
The drug loading efficiency of these Ag2S QDs is high
compared to that with other methods and QDs. Silica
nanoparticles (NPs) were also observed to absorb metformin
relative to the concentration of added material reaching a limit
for entrapment of 21% v/v relative to the silica NPs.18
Entrapment methods are limited by the storage efficiency of
internalized drugmolecules. For example, Xu et al.19 used hollow
zein NPs with an entrapment of 37% of metformin v/v
compared to the NPs. Comparatively, nanoparticles that have a
surface coat of drug molecules retain more drug molecules. With
regards to binding metformin, PLGA NPs retained 66−
68%;20,21 gold NPs retained 63%;22 pectin NPs retained
68%,23 and BSA NPs retained 92%.24
Biodistribution and Pharmacokinetics of QD-Metfor-
min. Nanomaterial drug transporters alter the biodistribution
and pharmacokinetic properties of drugs.25 To investigate the
effect of conjugation of metformin to QDs, radiolabeled (14C)
metformin was attached to tritium (3H)-labeled QDs. The
results demonstrated that QDs substantially alter the distribu-
tion and pharmacokinetics of metformin. QD-metformin had
25% increase in area under the curve (AUC) in the liver and
blood and 60% lower AUC in the small intestine compared to
that with metformin alone (Figure 2).
Unconjugated metformin took 8 h for half the dose to be
absorbed from the small intestine, and at this time point, only
25% of the ingested dosage was distributed into the liver. This
decreased to 5% at 24 h (Figure 2A). This indicates that only
25% of the dose of oral metformin is acting in the liver to
promote hepatic glycemic regulation. Oral bioavailability is
usually assessed from the concentration of a drug in the blood,
and metformin has an oral bioavailability of 40−60% under
fasting conditions; however, this is lower in the fed state.26,27
Data on the distribution into the target organ, in this case the
liver, are critical because it directly influences pharmacological
responses.
Comparatively, (3H)QDs and (14C)metformin bound toQDs
had a rapid clearance from the small intestine with only 25% of
the ingested dosage remaining in the small intestine 30min post-
administration (Figure 2B). By the 2 h time point, 50% of the
ingested dose was found in the liver and 10% in the blood and
the kidneys. The blood concentration of QDs and metformin
peaked at the 2 h time point, and the 3H and 14C radiolabels had
similar distribution patterns until the 8 h time point (Figure 2).
As no differences were observed between (3H)QD and QD-
(14C)metformin, this suggests that the difference in their
hydrodynamic diameter does not influence uptake from the
small intestine and that the low pH environment of the stomach
does not dissociate metformin from the QD prior to absorption
into blood.
After 8 h, the amount of drug and QDs in tissues and blood
decreased, and this was associated with an increase in fecal
elimination (Figure 2C). (14C)metformin bound toQDs did not
show the same increase in fecal elimination that was observed
with QDs up to 24 h (Figure 2C); however, it did show an earlier
peak in kidney tissue. These results suggest that the bond
between metformin andQDs is cleaved in the liver, and the QDs
are eliminated primarily via the bile and feces, while metformin
is excreted via the urine. The bond between the QD and
metformin is an amide bridge; therefore, it is likely that the
cleavage of this bond is undertaken by hepatic cytochrome P450
enzymes.28
Overall, the biodistribution data highlight that metformin
transported to the liver by QDs enters the hepatocytes and
persists for up to 24 h.10 The liver has a wide range of effective
processes to metabolize and eliminate xenobiotics including
most drugs and nanomaterials. There are multiple potential
barriers to prevent the uptake of nanomaterials including
endocytosis and phagocytosis by Kupffer cells, LSECs, and
infiltrating macrophages. Once taken up by hepatocytes, phase I
and phase II metabolism combined with efficient biliary
excretion ensure rapid metabolism and clearance of xenobiotics.
Metformin is released fromQDs into the hepatocytes during this
process with QDs cleared into the bile for fecal elimination. It is
of note that nanocrystallization of medicines are associated with
similar improvements in biodistribution of medicines.25,29 It is
generally considered that nanocrystal medicines have greater
bioavailability due to improved solubility and not cellular
targeting.29,30 Our results also raise the possibility that the
improved bioavailability of nanocrystals may also be due to their
size-dependent uptake in the small intestine and liver.31
Pharmacodynamic Properties of QD-Metformin and
QD-NMN. To characterize the pharmacodynamic properties of
QD-metformin and QD-NMN, we compared the in vivo dose−
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response effects with the nonconjugated medicines. A single oral
dose of metformin or NMNwith or without conjugation to QDs
reduced blood glucose levels in oral glucose tolerance tests
(oGTT) in 3 month old mice. Metformin when given alone 2 h
prior to oGTT had a maximal effect of a 75% reduction in the
AUC at a dose of 100mg/kg (Figure 3A). Comparatively, a dose
of only 2.4 mg/kg of QD-metformin was required to promote
the same reduction in AUC (Figure 3B). There were no
differences in the shape of the oGTT curves and metformin and
QD-metformin had similar Tmax. Overall, a 100-fold lower dose
Figure 3. In vivo pharmacodynamics and PK/PD of metformin and NMNwith and without attachment to QDs. (A)Metformin (black) and (B)
QD-metformin (red) given by oral gavage 2 h prior to an oral glucose tolerance test (oGTT) demonstrated a dose-dependent reduction in the
time taken to clear glucose from the blood and AUC. (C) Comparison between dosage of metformin alone and QD-metformin and the
percentage of reduction in oGTT AUC demonstrates QD-metformin induces the same effect as drug alone at 1% of the dosage given. (D)
Comparison of the effects of the same dosage of metformin with/without conjugation to QDs on the reduction in oGTT AUC. oGTTs were
performed 0.5, 2, 4, 8, or 24 h following gavage. (E) NMN (greenh) and (F) QD-NMN (blue) given by oral gavage 2 h prior to an oGTT
demonstrated a dose-dependent reduction in the time taken to clear glucose from the blood and AUC. (G) Comparison in the concentration of
drug given between NMN alone and QD-NMN and the percentage of reduction in oGTT AUC demonstrates QD-NMN induces the same effect
as drug alone at 0.1% of the dosage given. (D) Comparison of the effects of the same dosage of NMN with/without conjugation to QDs on the
reduction in oGTTAUC. oGTTs were performed 0.5, 2, 4, 8, or 24 h following gavage. Data showmean± SD (n = 3 per group). Statistical test:
Kruskal−Wallis tests with a post-hoc Dunn’s method; α = 0.05.
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of QD-metformin promoted comparable effects to metformin
alone (i.e., 2 log10 left shift in AUC50) (Figure 3C). The optimal
time for administering metformin was 4 h prior to oGTT, while
for QD-metformin, it was only 2 h, consistent with its more rapid
absorption and uptake by the liver. This shift in optimal timing
of the dose correlates with the peak concentration of
(14C)metformin within the liver (Figure 2A). When the same
doses of metformin with and without QD conjugation were
administered between 0.5 to 24 h prior to oGTT, it was found
that QD-metformin had a greater effect in reducing the oGTT
response at all time points (Figure 3D) up until 24 h when no
effect was seen with either treatment.
There have been a few other studies evaluating the effects of
nanocarriers on the pharmacodynamic effects of metformin in
Figure 4. In vivomolecular pathways promoted by QD-drug treatment compared to drug alone. Mice received an oral gavage of water (white),
QDs (gray), QD-metformin (red), metformin (black), QD-NMN (blue) or NMN (green) (dosages are given per figure) 2 h prior to liver tissue
collection and hepatocyte and liver endothelial cell isolations. (A) p-AMPK/AMPK and (B) SIRT1 were analyzed by Western blots and
normalized to β-tubulin expression, percentage changes relative to untreated controls are compared between groups. (C) cGMP by a
commercial ELISA, and (D) NAD total, NAD+ and NADH by a commercial NAD/NADH assay. Westernblot images are provided in
Supplementary Figure 2. ELISA and assay proteinmeasurements are relative tomg of liver tissue or protein from isolated cells. Data showmean
± SD (A,B: n = 5, C−D: n = 3 per group). Statistical test: (A,B) one-way-ANOVA with post-hoc Bonferroni test; (C,D) Kruskal−Wallis tests
with a post-hoc Dunn’s method; α = 0.05.
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vivo.32 PLGA nanoparticles loaded with metformin (10 mg/kg)
reduced the AUC of oGTTs streptozotocin-treated diabetic rats
by 60% when given by injection 30 min prior to the glucose
dose.20 In a similar study, oral alginate nanocapsules loaded with
metformin (46.7 mg/kg) reduced the AUC of oGTT by 20%
compared with metformin alone administered by injection (150
mg/kg).22 The QD-metformin used in our study has
considerably greater potency than the metformin nano-
medicines reported in these studies. Moreover, our QD-
metformin was administered orally compared to these previous
studies where the metformin nanomedicines were administered
by injection.
NMNwas not as potent as metformin in terms of reducing the
AUC of the oGTT. NMN given alone promoted a maximal 50%
reduction in the AUC at a dose of 8000 mg/kg (Figure 3E),
while QD-NMN led to a similar reduction in the oGTT at a dose
of only 0.8 mg/kg (Figure 3F). Overall, QD-NMN achieved the
same effect on oGTT with 1/1000 of the dose NMN alone
(Figure 3G). Examining a range of time points from 0.5 to 24 h,
it was found that QD-NMNhad its optimal effect when given 2 h
prior to oGTT, while NMN alone was optimal when given 4 h
prior to oGTT. At all dosing time points, QD-NMN had a
greater effect on oGTT than equidoses of NMN alone (Figure
3H). As far as we are aware, other nanocarrier methods for the
drug delivery of NMN (or related compounds, NAD+ or
nicotinamide riboside) have not been reported. Our studies
indicate that Ag2S QDs are very effective carriers for the hepatic
uptake of NMN.
Mechanisms for the Uptake and Activity of QD-
Metformin and QD-NMN. The majority of nanomaterials
are taken up by cells via endocytosis.33 Endocytosis is
undertaken by clathrin- and caveolin-mediated pathways and
micropinocytosis and is geared toward subsequent degradation
of materials within lysosomes,33,34 which of course limits the
effect of nanomedicines. Therefore, we investigated the
mechanisms for the cellular uptake of QD-metformin and
Figure 5. In vitro drug/QD-drug treatment on isolated hepatocyte endocytosis/activation and LSEC fenestrations. Hepatocytes were isolated
from young 3 months old mice (A) and old 18 months old mice (B). Hepatocytes were nonpretreated control (CNTR) or pretreated for 0.5 h
with sucrose (0.5 M) to block clathrin-mediated endocytosis and micropinocytosis or omeprazole (10 μM) to block endocytosis via protein
pumps. Cells were then treated for 2 h with radiolabeled (14C)metformin (black) or QD(14C)metformin (red). (C) Young and (D) old
hepatocytes were isolated and either nonpretreated or pretreated with sucrose (stripes) or cytidine 5-monophosphate (CMP) (spots) an
inhibitor of dephosphorylation of NMN.Cells were then treated withQD-NMN(blue) orNMN (green) for 2 h. Cells were then lysed andNAD+
measured by NAD/NADH assay. (E) Young hepatocytes were isolated and incubated for 2 h with increasing concentration of QDs (1 nM to 10
mM). Cell viability was measured with an MTT assay. Data show mean± SD (n = 3 per group, compared with Kruskal−Wallis tests and post-
hoc Dunn’s method; α = 0.05).
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QD-NMN and compared the effects of these drugs, with and
without conjugation to QDs, on their intracellular targets.
Metformin acts via phosphorylation of AMPK and activates
cGMP downstream of this, as we have reported in hepatocytes
Figure 6. Overview of 2-week in vivo treatment with QD-NMN (blue) and NMN (green) in 3, 18, and 24 month old mice on metabolic
parameters and toxicity. (A) schematic of experimental treatments and ages of intervention. (B−D) Effects of treatment in 3 month (B), 18
month (C), and 24 month (D) old mice. Data show liver NAD+, blood AST, and ALT; before and after treatment: oral glucose tolerance test
area under the curve (AUC), fasting and fed insulin and HOMA-IR. Comprehensive data shown in Supplementary Figures 3−6. Data show
mean ± SD (n = 5 per group). Statistical test: one-way-ANOVA with post-hoc Bonferroni test; α = 0.05.
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and LSECs.9,16 Mice treated with either metformin or QD-
metformin demonstrated upregulation of pAMPK/AMPK and
cGMP in hepatocytes following doses of 100 mg/kg metformin
and 4 mg/kg QD-metformin (Figure 4A and Supplementary
Figure 2). QD-metformin, but not metformin alone, promoted
activation of AMPK in LSECs (Figure 4A and Supplementary
Figure 2). This is consistent with our previous study showing
uptake of Ag2S QDs by LSECs.
10 Treatment of the immortal
LSEC cell line, SK-Hep1, with metformin demonstrates
upregulation of pAMPK and production of endothelial nitric
oxide synthase (eNOS) (Supplementary Figure 3). Previously,
we showed a 12 month 0.1% metformin diet (75 mg/kg/day)
from 3 to 15 months in mice induces liver endothelium
fenestration changes, suggesting AMPK activation in these cells;
however, this required prolonged treatment.16
Mice treated with either NMN or QD-NMN demonstrated
similar effects on SIRT1 activity, total NAD and NAD+ in liver,
hepatocytes, and LSECs (Figure 4 and Supplementary Figure
2). Similar increases in total NAD and NAD+ were observed for
800 mg/kg NMN and 8 mg/kg QD-NMN treatments. QD-
NMN, but not NMN alone, increased these concentrations in
LSECs (Figure 4D). Within the SK-Hep1 cell line, QD-NMN
promotes upregulation of SIRT1, pAMPK, eNOS, and
peroxisome proliferator-activated receptor γ coactivator 1α
(PCG-1α) (Supplementary Figure 3). Together these data
indicate that the treatment effects of both metformin and NMN
on their intracellular targets in hepatocytes are not influenced by
conjugation with QDs and that conjugation enables consid-
erably less dosage to be administered to achieve the same
treatment effect. However, conjugation with QDs leads to
additional effects on LSECs because these cells avidly take up
QDs.
Comparisons of the effectiveness of QD-metformin to QD-
NMN indicate that QD-NMN allows for a greater reduction in
dosage (compared to NMN) than with QD-metformin
(compared to metformin alone). Mice treated with QD-NMN
(8 mg/kg) had a greater increase in pAMPK/AMPK and SIRT1
than mice treated with QD-metformin (4 mg/kg) in the isolated
hepatocytes and LSECs (Figure 4A−C). This effect may be due
to the improved transport of QD-NMN across the small
intestine and prevention of the utilization by gut microbiota
(NMN is readily used by, and facilitates growth of E. coli),35 a
wider therapeutic effect window (0.01−10 mg/kg QD-NMN vs
0.2−5 mg/kg QD-metformin (Figure 3C,G), and greater
cellular activation of AMPK and SIRT1 with QD-NMN
compared to QD-metformin (Figure 4A,C).
The cellular uptake of metformin is usually mediated by the
transporter OCT1, which is inhibited by omeprazole.36
Consistent with this, we found that omeprazole inhibited the
uptake of (14C)metformin by isolated hepatocytes from young
mice (Figure 5A). However, the uptake of (14C)metformin
conjugated with QDs was not inhibited by omeprazole. Instead,
the uptake of (14C)metformin conjugated with QDs was
inhibited by sucrose, which is an inhibitor of clathrin-mediated
endocytosis and micropinocytosis (Figure 5A). This result
indicates that conjugation of metformin with QDs changes its
cellular uptake from transport by OCT1 to clathrin-mediated
endocytosis in hepatocytes isolated from young mice.
A key finding from this work and our previous study10 is that
QDs and QDs coated with metformin are absorbed from the
small intestine and taken up by hepatocytes via clathrin-
mediated endocytosis. This is supported by our QD-NMN
experiments that also show clathrin-mediated endocytosis
(Figure 5C); furthermore, previous studies have shown
clathrin-mediated endocytosis of QDs in vitro and nanocrystals
in vivo.37,38 Overall this suggests that size, shape, and charge are
what facilitates this mechanism and that drug surface molecules
do not direct cellular absorption or uptake. An interesting
concept emerges from this; nanoreformulations of oral drug
molecules have greater bioavailability and improved pharmaco-
dynamics than the drug molecule alone,25 and these nanocrystal
structures may also be taken up by clathrin-mediated
endocytosis. Nanoreformulation of drug molecules has a high
cost for research and development and toxicity and safety
testing,39 and it may be possible that using a core nanocrystal
and attachment of the drug to the surface may perform the same
function as these reformulations without costly development
and testing.
Hepatocytes isolated from old mice exhibited overall reduced
endocytosis compared to young mice (Figure 5B), but the
effects of omeprazole and sucrose on metformin uptake were
similar to those seen in young mice. However, in hepatocytes
isolated from old mice, uptake of metformin was greater when it
was bound to QDs compared to metformin alone (Figure 5B).
The cellular uptake of NMN requires dephosphorylation to
nicotinamide riboside for transport into hepatocytes, then
rephosphorylation before being used to replenish NAD+
levels.40 Treatment of hepatocytes isolated from both young
and old mice with NMN or QD-NMN led to increased NAD
and NAD+ levels. Pretreatment with cytidine 5′-monophos-
phate, an inhibitor of NMN dephosphorylation,40 inhibited the
uptake of NMN by hepatocytes (Figure 5C,D); however, QD-
NMN was unaffected by cytidine 5′-monophosphate pretreat-
ment, highlighting again a change in cellular uptake pathway
(Figure 5C,D). Overall, treatment response was substantially
lower in hepatocytes from oldmice. The in vitro effect of QDs on
cell viability in isolated hepatocytes from young mice was also
examined in these experiments. Cell viability was influenced
only whenQD concentration exceeded 256 μg/mL (Figure 5E).
Effects of 2 Weeks of Treatment with QD-NMN versus
NMN in Young and Old Mice. NMN improves metabolic
outcomes and influences the aging process. Old age influences
metabolic outcomes, with an increase in insulin resistance and
prevalence of diabetes mellitus. A previous study has shown that
NMN improved oGTT in old diabetic animals,15 and NAD
levels decline with increasing age.41 Here, we carried out in vivo
experiments to determine whether QD-NMN, which only
targets the liver, has metabolic outcomes similar to that with
NMN alone, which is systemically bioavailable. We also wanted
to determine whether the substantial increase in the potency of
QD-NMN that we demonstrated in acute in vitro experiments
was retained in longer term studies under in vivo conditions. To
determine the effects of old age on these outcomes, three age
groups were studied: 3, 18, and 24 months of age. In these
studies, mice were treated for 2 weeks with QD-NMN (8 mg/
kg/day) or NMN (800 mg/kg/day) administered in drinking
water (Figure 6A and Supplementary Figures 4−7).
In 3 month old mice, QD-NMN and NMN both improved
the oGTT and increased liver total NAD and NAD+ levels by 3-
fold but had no effects on body weight, insulin, or HOMA-IR
(Figure 6B and Supplementary Figures 4 and 7). There were no
differences in these responses between QD-NMN and NMN
despite the 100-fold difference in dose.
Eighteen month old mice showed higher insulin levels, higher
HOMA-IR, and lower total NAD and NAD+ levels in the liver
compared to those in young mice. In mice aged 18 months, QD-
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NMN, but not NMN alone, was associated with lower fed and
fasted insulin levels and lower HOMA-IR (Figure 6C and
Supplementary Figures 5 and 7). In mice aged 24 months, QD-
NMN, but not NMN alone, was associated with improved
oGTT and lower fasting insulin and lower HOMA-IR (Figure
6D and Supplementary Figures 6 and 7).
Insulin and glucose metabolism in the liver are influenced by
NAD levels,9,42 which decrease with old age.41 In our study, the
oldest mice (24 months) displayed lower levels of NAD+ and
higher levels of insulin and HOMA-IR compared to the
youngest mice (3 months), consistent with other reports.15
Over 2 weeks, a low dose of orally administered QD-NMN led
to increased liver NAD+ levels and decreased insulin and
HOMA-IR values in old mice. The dose of QD-NMN (8 mg/
kg/day) is substantially less than the dose of NMN alone (800
mg/kg/day) or the dose reported by Yoshino et al.15 (500 mg/
kg/day by intraperitoneal injection) in their study of NMN
supplementation in old diabetic mice. These results confirm that
conjugation to Ag2S QDs greatly enhances the hepatic targeting
of NMN, which is translated into beneficial metabolic outcomes.
There was some indication that QD-NMN was having a
greater effect on liver NAD+ levels than NMN alone. This might
explain the greater effect of QD-NMN than NMN alone on
metabolic outcomes in the older mice. However, the difference
in NAD+ levels is not significant and raises the possibility that
QD-NMN is influencing glucose and insulin metabolism via an
additional mechanism that is independent of hepatocyte NAD
levels. We previously found that fenestrations in the LSECs are
the portal for the transfer of insulin from blood to hepatocytes.43
Loss of fenestrations occurs with old age, and this increases the
barrier for the uptake of insulin and contributes to insulin
resistance.44 Moreover, we found that NMN can increase
fenestrations and that drugs conjugated to Ag2SQDs are actively
endocytosed by the LSECs.
Therefore, the uptake of QD-NMN by LSECs might also
improve insulin resistance in the liver by increasing fenestrations
in these cells. We then studied the effect of QD-NMN on
Figure 7. Effects of 100 day in vivo treatment with QDs (320 μg/kg/day). (A) Body weight of mice was collected every 7 days with control
(CNTR) collected at day 0 and 100. (B) AST and ALT were not significantly influenced by treatment. (C) No changes in plasma IL-6, MIP-2
(mouse homologue of IL-8), or IFN-γwere observed. (D)H&E staining of the liver demonstrated sparse immune cell infiltration inQD-treated
mice with no other pathohistological features. (E) TNFα staining did not show differences between CNTR and QD-treated mice, positive and
negative control section from the spleen of control tissue. (F) Sirius Red staining of the liver and kidney (G) did not show differences between
groups with lowminimal fibrosis of the portal vein nor were differences observed in theMETAVIR fibrosis score. In the kidney, no enlargement
of the Bowman’s capsules in the kidney was observed, and no change in plasma creatinine was shown. Data show mean± SD (n = 5 per group
compared with one-way-ANOVA and post-hoc Bonferroni test); α = 0.05.
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fenestrations. Isolated LSECs were collected and treated with
QD-NMN (25 μg/mL) and NMN (250 μg/mL). Scanning
electron microscopy demonstrated both QD-NMN and NMN
treatments increased the area covered by, and the number, of
fenestrations (Supplementary Figure 8A−D). QD-NMN had a
3-fold greater effect that NMN treatment with, NMN given at a
10-fold dosage compared to QD-NMN. No overall differences
in diameter were observed; however, a histogram of fenestration
diameter demonstrated a shift toward larger fenestrations in
NMN-treated cells (Supplementary Figure 8E).
Short- and Long-Term Toxicity of QDs and QD Drug
Treatments. Short- and long-term toxicity was evaluated after
14 (250 μg/kg/day) and 100 days (320 μg/kg/day) of
continuous treatment with QDs delivered via drinking water.
There were no effects on AST or ALT levels, or liver, spleen,
kidney, or small intestinal histology after 2 weeks treatment in
mice aged 3, 18, or 24 months (Supplementary Figure 7).
One hundred days of continuous treatment was performed in
mice aged 8−12 months. Mice demonstrated increased and
sustained body weight growth during this period (Figure 7A).
Long-term treatment did not lead to any significant changes in
body weight or blood AST or ALT (Figure 7B). Histological
examination only found minimal inflammatory cell infiltration
after 100 days (Figure 7C). However, in subsequent
investigations, there were no differences in liver TNFα
expression or circulating IL-6 or IFN-γ levels to suggest a
sustained inflammatory response (Figure 7D,E). Neutrophil
infiltration in the absence of a pro-inflammatory state was
evaluated with MIP-2,45 and no changes in plasma levels were
detected (Figure 7D). Within the liver and kidneys, there were
no changes in the METAVIR fibrosis score,46,47 thickening of
the glomeruli, or plasma creatinine between treated and
untreated mice (Figure 7F,G).48 Overall, the data suggest that
320 μg/kg/day (100 days) Ag2S QDs is not toxic, mostly likely
as a result of rapid clearance by the liver.10 This was then further
investigated.
Ag2S and other QDs form a protein corona of basic circulating
blood proteins including albumin,10,49 leading to less recog-
Figure 8. Autometallography staining of the liver and small intestine and inductively coupled plasma mass spectrometry. (A)
Autometallography is a measure of silver distribution and involves adding additional silver to aggregate to silver ions in tissue sections.
Liver panels show untreated negative control, 250 μg/kg treated, and 250 μg/kg treated with a 3 day wash out prior to tissue collection. Staining
of the endothelium is absent in the 3 day wash out compared to the treated sample. Fourteen day (250 μg/kg/day) and 100 day (320 μg/kg/day)
treated mice demonstrate staining in the sinusoids of the liver and of the bile ducts. The 7500 μg/kg (toxic dosage) shows silver staining in all
tissue compartments with aggregates in hepatocytes. Small intestine panels show silver staining in the blood vessel underlining the villi. (B)
ICP-MS was performed was performed on liver tissue samples to analysis the concentration of Ag+. No differences were observed between
groups, one 100 day sample demonstrated elevated Ag+ content with data shownwith andwithout outlier (statistical test: one-way ANOVAwith
post-hoc Bonferroni test); α = 0.05. Cells were then incubated with Alexa Fluor 488 goat anti-rabbit, 1% goat serum in PBS for 30 min at 4 °C.
Cells were again centrifuged, washed in PBS twice with centrifugation between washes.
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nition by complement opsonization and immune cells compared
to larger nanoparticles (in part due their smaller dynamic
size);50,51 however, the trade-off of this is rapid clearance by the
liver.52 This clearance of nanoparticles via non-Kupffer cell
pathways over 72 h has been demonstrated by Poon et al.53
Uptake by Kupffer cells is understood to result in retention of
nanoparticles with subsequent toxicity.53 To further examine the
accumulation and clearance of QDs, autometallography of
silver54 was performed on the liver following: untreated, 2 h after
a single oral gavage of QDs (250 μg/kg), 72 h after a single oral
gavage of QDs (250 μg/kg), 14 day continuous treatment (250
μg/kg/day), 100 day continuous treatment (320 μg/kg/day),
24 h after a single oral 7500 μg/kg gavage of QDs and small
intestine 2 h after single oral gavage of QDs (250 μg/kg) (Figure
8). Silver was detected in all liver samples, excluding untreated
mice, and was present in the blood vessels of the small intestine.
We observed that following a 3 day wash out period, there was a
reduction in silver staining in the endothelium in the liver
(Figure 8A) and that there was no greater accumulation of silver
in 14 versus 100 day treatments (Figure 8A), which indicates that
the QDs are not accumulating and are being cleared from the
liver. Staining in these continuous treatment samples was
localized to the endothelium but not Kupffer cells and did not
show aggregation in hepatocytes. Comparatively, high dosage
and toxic treatment demonstrated aggregates within hepatocytes
and a disrupted endothelium (Figure 8A).
To confirm this finding, inductively coupled plasma mass
spectrometry (ICP-MS) was performed on liver samples from
control, 14 day (250 μg/kg/day), and 100 day QD-treated mice
(320 μg/kg/day). ICP-MS detection of Ag+ ions was observed
in low concentrations in both 14- and 100-day-treated samples
compared to control or blank tissue samples (Figure 8B).
Comparing 14 and 100 day liver samples, no differences in Ag+
ion content were observed. This supports the silver staining data
shown in Figure 8A and demonstrates that the QDs are not
accumulating within the liver over 14 or 100 day treatment and
with no aggregation in Kupffer cells observed. Together this
indicates that clearance is non-Kupffer cell mediated.6
Overall, previous nanoparticle toxicity studies,6 have demon-
strated cellular necrosis, immune cell infiltration, increased
inflammatory marker expression, oxidative stress, liver fibrosis,
and impaired function of the liver and kidneys. We found no
evidence for any such toxicity following 100 days of continuous
treatment with 320 μg/kg/day QDs.
Clinical Relevance. Clinically, metformin is the first line
treatment for type II diabetes mellitus and is currently under
investigation for its therapeutic role in aging.55 Metformin is
considered a safe and reliable medication in both the young and
older population; taken as a therapeutic agent, it lowers blood
glucose, improves insulin resistance, and promotes weight loss.55
Taken preventatively with lifestyle intervention, metformin
reduces the incidence of type II diabetes mellitus.56 In the aging
population, metformin outperforms and causes less harm in
patients >65 years of age compared to alternative medications.57
However, there are limitations with metformin treatment. First,
gastro-intestinal side effects develop in 25% of patients, with this
directly related to high metformin concentrations in the
intestine and liver.58 Excess lactate production mediates this
side effect, with previous studies showing the intestine is the
primary site of this lactate production (as reviewed inMcCreight
et al.).59 Second, metformin requires the OCT1 transporter for
both its intestinal and hepatic uptake with intolerance to
metformin caused by polymorphisms in this transporter.58 This
report also observed that intolerance tometformin (via impaired
OCT1 uptake) also increases with age. QD-metformin may be a
solution to these issues. QD-metformin has reduced intestinal
availability and may reduce lactate and gastrointestinal
discomfort in patients compared to metformin alone. QD-
metformin does not require the OCT1 transporter for
absorption by both intestinal and hepatic cells; therefore,
intolerance and impaired uptake with aging may be overcome
using our QD formulation.
The clinical effectiveness of NMN is an area of increasing
interest, the receptor responsible for its uptake into cells has
recently been reported;60 however, it is unclear if the
effectiveness of NMN absorption and cellular uptake is reduced
with aging. We have demonstrated that QD-NMN can
outperform NMN alone in 24 month old mice and reverses
age-associated HOMA insulin resistance with NMN treatment
being ineffective over 2 weeks. We have, however, not shown its
long-term benefit. The key effect of QD-NMN compared to
NMN in this study is the activation of SIRT1 pathways in the
liver endothelium in addition to hepatocytes. These cells
facilitate the passive diffusion of glucose and insulin into the
liver (a function reduced with increased age), this is not only
critical for hepatic insulin sensitivity but preserving the liver
microenvironment in aging and metabolic diseases.11,61 Finally,
as QD-NMN is primarily targeted to the liver, it demonstrates
that the metabolic functions of NMN are performed by the liver
as proposed by Hunt et al.9
Future Directions. It has been proposed that biomedical
research is at “the beginning of the end of the nanomedicine
hype” primarily because of the lack of successful translation of
nanomedicines for the treatment of cancer.62,63 However, the
liver is an important therapeutic target for metabolic disorders
and the aging process, and 80−95% of nanomaterials
accumulate and are cleared in the liver. The success of
nanomedicines will depend on directing research toward clinical
problems.64 Nanomedicines hold considerable promise for
targeting liver diseases and metabolic disorders regulated by the
liver.65 The Ag2S QDs in our study were very effective at
enhancing oral bioavailability and hepatoselectivity of NMNand
metformin with robust pharmacodynamic responses. QDs are
an ideal candidate for nanotheranostics development.66 Nano-
therapeutics that target the liver, rather than other sites, should
be at the forefront of nanomedicine research.
CONCLUSION
Ag2S QDs dramatically increased the hepatoselectivity of two
pharmaceutical agents acting on AMPK and SIRT1 pathways:
metformin and NMN. We have demonstrated that these QDs
can be utilized as effective nanocarriers that (i) have greater
biodistribution and selective uptake in the liver compared to the
drug alone; (ii) utilize lower doses of the drug; (iii) have greater
physiological effects at multiple time points post-treatment; (iv)
bypass drug specific receptor uptake into hepatocytes, mitigating
age-related decline in drug responses; (v) enhance the efficacy of
treatment by regulating the local microenvironment via
controlling the drug uptake in neighboring LSECs; and (vi)
demonstrate negligible cellular toxicity, inflammation or tissue
damage for at least 100 days of daily intake.
EXPERIMENTAL PROCEDURES
Ethics. The study was approved by the Animal Welfare Committee
of the Sydney Local Health District and was performed in accordance
with the Australian Code of Practice for the care and use of animals for
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scientific research (AWC approval: 2016/010 and 2018/010). All
information provided accords with the ARRIVE guidelines.
Materials. Silver diethyldithiocarbamate (cat no. D93503, Merck,
AUS), 1-dodecanethiol (cat no. 471364 Merck, AUS), cyclohexane
(Merck, AUS), ethanol (Merck, AUS), xylene (Merck, AUS), acetone
(Merck, AUS), N2 gas (BOC, AUS), Ar gas (BOC, AUS), 3-
mercaptopropionic acid [3-MPA] (cat no. M5801, Merek, AUS),
metformin (cat no. D150959, Merck, AUS), nicotinamide mono-
nucleotide (gift from Dr. Lindsay Wu, University of New South Wales,
Australia), (14C)metformin (cat no. MC-2023, Moravek, USA),
(3H)oleic acid (cat no. O-1518, Merck, AUS), N-(3-(dimethylamino)-
propyl)-N′-ethyl carbodiimide hydrochloride [EDC] (cat no. E6383
Merek, AUS), N-hydroxysulfosuccinimide sodium salt [NHS] (cat no.
56485, Merek, AUS), SnakeSkin dialysis tubing 10,000 MWCO (cat
no. 88243, ThermoFisher Scientific, AUS), scintillation fluid (Ultima
Gold 2x, cat no. 6013329, PerkinElmer, AUS), 30% H2O2 (cat no.
18312,Merck, AUS), solvable solution (cat no. 6NE9100, PerkinElmer,
AUS), cytidine monophosphate (cat no. C1131, Merck, AUS), sucrose
(cat no. S7903,Merck, AUS), omeprazole (cat no. O104,Merck, AUS),
collagenase (type 1, cat no. 47D17410A, ProSciTech, AUS), RPMI-
1640 (Merek, AUS), DMEM (Merck, AUS), fetal calf serum (Merck,
AUS), Percoll (Merek, AUS), penicillin-streptomycin (Merek, AUS),
Whatman grade 4 filter paper (Merck, AUS), dimethyl sulfoxide
(Merek, AUS), in vitro toxicology assay kit, MTT kit (cat no. TOX1-
1KT, Sigma-Aldrich, AUS), AST activity assay (cat no. MAK055,
Merck, AUS), ALT activity assay (cat no. MAK052, Merck, AUS),
creatinine assay kit (cat no. MAK080, Merck, AUS), IL-6 ELISA Kit,
mouse (cat no. ab100712, Abcam, AUS), NAD/NADH quantification
kit (cat no. MAK037, Merck, AUS), MIP-2/CXCL2Mouse ELISA kit
(cat no. ab100727, Abcam, AUS), IFN gamma mouse ELISA kit (cat
no. ab100689, Abcam, AUS), cyclic guanosine monophosphate ELISA
kit (cat no. 581021, Sapphire Bioscience, AUS), cyclic guanosine
monophosphate (cGMP) ELISA kit (cat no. 581021, Sapphire
Bioscience, AUS), ultrasensitive mouse insulin ELISA kit (cat no. 80-
INSMSU-E01, ALPCO, USA), D-(+)-glucose (cat no. G7528, Merck,
AUS), Accu-Chek Performa strips (cat no. p-4015630981946, Amcal,
AUS), Accu-Chek Performa blood glucose meter kit (cat no. p-
4015630982219, Amcal, AUS), and insulin ELISA kit, mouse (cat no.
90080, Crystal Chem Inc., USA), SIRT1 antibody (cat no. 05-1243,
Merck, AUS), TNF-α antibody (cat no. ab1793 Abcam, AUS), p-eNOS
antibody (Ser1177, cat no. 9571, Genesearch, AUS), eNOS antibody
(type 3, cat no. 610296, BD Bioscience, AUS), goat anti-rabbit IgG (H
+L) secondary antibody (cat no. 31460, ThermoFisher, AUS), 16-well
Grace Bio-Laboratories CultureWell (cat no. GBL112358, Merck,
AUS), p-AMPKα antibody (Thr172, cat no. 2531, Cell Signaling
Technology, AUS), IRS-1 antibody (cat no. 2382, Cell Signaling
Technology, AUS), IRS-2 antibody (cat no. 4502, Cell Signaling
Technology, AUS), PCG-1α antibody (cat no. 2178, Cell Signaling
Technology, AUS), AMPKα antibody (cat no. 2532, Australian
Biosearch, AUS), Lyve1 antibody [EPR21771] (cat no. ab218535,
Abcam, AUS), β-tubulin antibody (cat no. 2146, Cell Signaling
Technology, AUS), Tom20 antibody (cat no. 42406, Cell Signaling
Technology, AUS), Alexa Fluor 488 goat anti-rabbit (cat no. R-37116;
Thermo Fisher AUS). Western blot reagents were as follows: loading
buffer (cat no. B0007, Thermo Fisher), running buffer (cat no. B0001,
Thermo Fisher), transfer buffer (cat no. BT00061, Thermo Fisher),
Ponceau staining (cat no. P7170, Sigma-Aldrich), Precision Plus
Protein Western Standards (cat no. 1610376, BioRad, AUS), PBS
tablets (cat no. P4417, Merck, AUS), Tween-20 (cat no. P1379, Merck,
AUS), silver lactate (cat no. 359750, Merck, AUS), hydroquinone (cat
no. H9003, Merck, AUS), sodium thiosulfate (cat no. 72049, Merck,
AUS), and carboxymethyl cellulose (cat no. C4888, Merck, AUS).
Synthesis of Water-Soluble Ag2S QDs. Ag2S QD synthesis has
previously been reported.10,67 Briefly, 0.1 mM silver diethyldithiocar-
bamate was mixed with 12 mL of 1-dodecanethiol under vigorous
magnetic stirring. A N2 vacuum was created followed by an Ar vacuum
to remove oxygen from the mixture. The solution was heated to 200 °C
at a rate of 12 °C/min and held at this temperature for 1 h. Following
synthesis, EtOH was added to the solution followed by centrifugation.
Ag2S QDs were resuspended in minimal cyclohexane, washed twice
with EtOH, with each wash resulting in precipitation of Ag2S QDs and
isolated with centrifugation. Aqueous phase transfer was performed
with QDs suspended in a 1:1 (v/v) mixture of cyclohexane and acetone
under magnetic stirring. One milliliter of 3-mercaptopropionic acid was
added per 25 mg of Ag2S QDs and mixed at room temperature for 1 h.
Following this, QDs were mixed with EtOH and centrifuged. The pellet
was redispersed in minimal MQ, washed with EtOH twice, and
dispersed in MQ. Samples was then filtered using Whatman grade 4
filter paper. QDs were diluted to 10 mM for storage at 4 °C in the dark.
DrugAttachment.Metformin andNMNwere attached toQDs via
EDC/NHS coupling. Ag2S QD (1 mM) was mixed with 1 mM EDC
and 1 mMNHS in a reaction vial under heavy mixing for 1 h. Following
this, the pH was not altered for metformin or increased to pH 9 with 1
mM (final volume) Na2CO3, and metformin or NMNwas added to the
solution. The solution was mixed overnight and transferred to dialysis
tubing 10,000 MWCO and dialyzed with 1 mL solution per 1 L of MQ
for 2, 4, and 16 h at 4 °C in the dark. Drug and QD-drug concentrations
were determined using a Nanodrop UV−vis spectrophotometer for
protein absorbance 205−280 nm (ThermoFisher, AUS).
Fourier Transform Infrared Microscopy. Confirmation of the
deposition onQDs was performed using FTIR. FTIRwas performed on
a LUMOS FTIR microscope (Bruker, USA), at the vibrational
spectrometry facilities at Sydney Analytical, the University of Sydney,
Australia. Samples were collected from dried QDwith a minimum of 10
measurements per material performed. Data show the average spectrum
across 3500−700 nm in ATR mode, following atmosphere correction
and normalization performed using OPUS 7.0 software (Bruker, USA).
An average spectrum was produced from 10 to 20 individual
measurements per material.
High-Voltage Transmission Electron Microscopy. Visualiza-
tion of QDs from nonbiological samples was performed using high
voltage transmission electron microscopy (HV-TEM). HV-TEM was
performed on a JEOL 2100 (JEOL, AUS), at the transmission electron
microscope facilities at the Australian Centre for Microscopy and
Microanalysis, the University of Sydney, Australia. Nonbiological
samples were prepared by evaporative deposition on carbon-based
TEM grids.
Zetasizer Characterization. Hydrodynamic diameter, PDI, and
zeta-potential were measured using a Zetasizer Nano ZS (Malvern
Bioanalytical, AUS), at Sydney Analytical, the University of Sydney,
Australia. Measurements were performed using 1 μM QDs, QD-
metformin or QD-NMN in MQ water. Hydrodynamic diameter size
and PDI measurements were performed using backscatter (173°) data
collection with three repeats of 12−15 measurements per sample. All
samples were analyzed in disposable folded capillary cells. Zeta-
potential was measured with five repeats of 10−12 measurements per
sample (maximal setting was 100 measurements). All data were
collected with triplicate data points.
Mice. C57BL/6J 3−4 month old and 12 month old mice were
obtained from the Animal Resource Centre in Perth, Western Australia.
Animals were housed at the ANZAC Research Institute animal house
on a 12 h light/dark cycle and provided with ad libitum access to food,
water, and enrichment. Mice were aged under these conditions until 18
or 24 months of age.
Radiolabeling. Tritium: 10 mM QDs were incubated at room
temperature with 0.5 μCi (3H)oleic acid for 3 h in a sonication bath and
24 h under Ar gas with vigorous stirring. Removal of excess oleic acid
was performed by two EtOH wash stages with centrifugation and
redispersion in minimal MQ.
Carbon-14: (14C)metformin was conjugated to QDs via EDC/NHS
coupling. One mM Ag2S QD was mixed with 1 mM EDC and 1 mM
NHS in a reaction vial under heavy mixing for 1 h. Following this, the
pH was not altered and 1.0 μCi (14C)metformin was added to the
solution. The solution was mixed overnight and transferred to dialysis
tubing 10,000 MWCO and dialyzed with 1 mL solution per 1 L of MQ
for 2, 4, and 16 h at 4 °C in the dark.
Tissue Collection. Mice were not fasted prior to gavage of QDs
with and without metformin or NMN for in vivo cellular mechanism or
radioactive biodistribution studies (Figures 2 and 4). Gavage was
performed using an esophageal gavage needle and delivered in a single
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rapid dose of 100 μL. Mice were euthanized by a single intraperitoneal
injection of 100 mg/kg ketamine and 10 mg/kg xylazine following all
experiments. Next, 200−250 mg of tissue samples was collected from
the liver, spleen, kidney, and small intestine along with 500 μL of plasma
blood collected via cardiac puncture. Tissue samples were snap frozen
with liquid N2 or placed in 2.5% glutaraldehyde/4% paraformaldehyde.
Sample Preparation and Radiolabeled Activity Analysis.
Tissue samples were weighed and mixed in a reaction vial with 1 mL of
solvable solution and incubated at 60 °C for 4 h to dissolve the tissue.
Next, 0.2 mL of 30% H2O2 was added to samples to reduce the dark
color saturation. Samples were mixed with 10 mL of scintillation fluid.
Radioactivity was measured using a scintillation counter (Tricarb 2100
TR, PerkinElmer, AUS). All samples were mixed with 10 mL of
scintillation fluid (five measurements per sample). Baseline measure-
ments were collected from control mice that were not treated with
radioactive QDs. Data were collected as disintegrations per minute and
used for analysis. All radioactivity data presented in this article used n =
3 mice per group for in vitro hepatocyte endocytosis, and the
experiments were performed in triplicate.
Hepatocyte and LSEC Isolation.The isolation of hepatocytes and
LSECs has previous been reported in our methods paper and our
previous studies.17,68,69 In brief, mice were anesthetized with a mixture
of 10 mg/kg xylazine and 100 mg/kg ketamine with liver cannulated via
the portal vein and perfused with Krebs buffer solution (0.142MNaCl,
6.71mMKCl, 9.63mMHEPES, and 4.6mMCaCl2) and collagenase at
37 °C. The liver was removed and dissociated by forceps in Krebs buffer
solution (without CaCl2) at 4 °C. Cells filtered and collected in Krebs
buffer solution (without CaCl2 but with 10g/L BSA). All centrifugation
steps, including the Percoll gradients, were performed at 4 °C.
Hepatocytes were isolated by three 10 min centrifugations at 50g. Dead
cells were removed by collecting the fraction between a two-step Percoll
gradient (40%, 50%). LSECs were collected from the hepatocyte
supernatant and isolated using another two-step Percoll gradient (25%,
45%) and centrifugation at 1350g. Kupffer cells were removed from the
LSEC fraction by selective adherence to plastic using two 8 min
incubations at 37 °C in RPMImedia. Cells were cultivated in serum free
RPMI-1640 media at 0.2 × 106 cells/cm2 on fibronectin-coated 16-well
chambered #1.5 coverslips at 37 °Cprior to use; however, they were not
stored >4 h prior to use. Cells were suspended in PBS followed by cell
counting, centrifuged, and prepared for either Western blots, assays, or
in vitro experimentation as described below.
Flow Cytometry. Purity of cell cultures was performed on a BD
LSR Fortessa X-20 flow cytometer (BD Biosciences, AUS) with data
analyzed on FlowJo (v20, FlowJo LLC, ON, USA). LSEC cell culture
purity (90%) was assessed using fluorescent marker staining. Following
cell isolation methods, LSECs were washed in PBS, centrifuged (1350g,
10 min, 4 °C), and incubated with anti-Lyve-1 primary antibody
(1:100) or rabbit IgG (1:100) and 1% goat serum in PBS for 30min at 4
°C. Cells were centrifuged and washed in PBS twice with centrifugation
between washes.
Hepatocytes cell culture purity (95%) were analyzed based on size
criteria and based on autofluorescence. Fifty thousand events were
collected per dilution, with events limited to size criteria. Results show
the sample data with linear and log10 scale ungated or following size
execution with 488 signal and 730 signals. All flow cytometry data in
Supplementary Figure 9 used n = 5 measurements.
Western B lots. Western blots were performed on isolated
hepatocytes and LSEC cells 2 h after gavage with QDs or QD-
metformin, QD-NMN, or untreated controls. Western blots were also
performed on in vitro-treated SK-Hep1 cells following 2 h treatment
with QDs or QD-metformin, QD-NMN, or untreated controls. Cells
were lysed using a Polytron homogenizer (PT1200E, Kinematica,
Germany) with total protein extracted as previously described.69 Bolt
tris-bis plus gels were run with negative control blank wells and positive
control samples known to contain the protein of interest. After transfer,
the PVDF membrane was incubated with primary antibodies to p-
AMPK, AMPK, SIRT1, peNOS, NOS, IRS-1, IRS-2, PCG-1α, Tom20,
and β-tubulin, followed by incubation with secondary antibody and
developed using ECL-Plus chemiluminescence detection solution.
Eachmembrane was analyzed per protein, striped, and stained for the β-
tubulin. Image data were collected using Image Lab 6.1 software
(BioRad, USA) with protein kDa determined using the automated
software in Image Lab software (BioRad, USA). Both the known
protein kDa and ladder type are used by the imaging software to
determine the band for analysis. Densitometry measurements were
performed using ImageJ software (NIH, USA). Protein expression was
normalized based on β-tubulin. Mean ± SD was calculated from 3 to 5
individual experiments.
Assays for Hepatocyte Metabolites. Assays for cGMP, NAD/
NADH, and MTT were performed using commercial kits as per their
instructions. Sample preparation buffers were provided in cGMP and
NAD/NADH kits with tissue and cells prepared using a Polytron
homogenizer, centrifugation, and analysis of the supernatant. Analysis
of cGMP and NAD/NADH in vitro-treated cells was performed using
sample preparation buffers and cells collected via cell scraper. Samples
were centrifuged with supernatant analyzed. MTT assays were
performed per instructions with incubation with MTT reagent and
cell lysis/color development with DMSO.
Assays for Toxicity and Immune Response. Assays for ALT,
AST, IL-6, MIP-2, IFN-γ, and creatinine were performed using
commercial kits per their instructions. Sample preparation buffers were
provided in kits with plasma samples were analyzed without additional
steps. Assays were performed in triplicate.
Cell Culture. The human SK-Hep1 cells were obtained from the
American Type Tissue Culture Collection (ATCC, USA) and were
cultured in a humidified 5% CO2 incubator at 37 °C. Cells were grown
in DMEM supplemented with 10% fetal calf serum and penicillin-
streptomycin. SK-Hep1 cells were starved for 4 h by removing FCS
from DMEM media. Cells were treated with 0.1 ng/mL QDs, QD-
metformin (0.1 and 1.6 ng/mL), and QD-NMN 0.1 and 3.2 ng/mL for
2 h prior to Western blot experimentation.
In Vitro Hepatocyte Endocytosis and NAD Generation.
Endocytosis assays of (3H)QDs, (14C)metformin, and QD-(14C)-
metformin uptake and NAD generation were performed using isolated
hepatocytes from young and old mice. Cells were plated at 0.25 × 106
cells in a 24-well plate with RPMI media. Cells were washed 2 h after
plating and incubated for 2 h before use. Cells were either untreated or
pretreated with inhibitors of (1) clathrin-mediated and micro-
pinocytosis endocytic pathways (sucrose; 0.5 M, 30 min), (2) cell
membrane protein pumps (omeprazole; 10 μM, 30 min), and (3)
phosphorylation competitive inhibitor (cytidine monophosphate; 2
mM, 1 h) in serum-free RPMI-1640 media. Hepatocytes were then
incubated with either 300 μL of (3H)QDs, (14C)metformin, and QD-
(14C)metformin in DMPI without phenol red or 300 μL NMN or QD-
NMN for 2 h at 37 °C.
For analysis of endocytosis of radiolabeled substrates, two fractions
were collected: cell media and lysed cells. Cells were lysed with 0.1%
SDS solution and collected using a cell scraper. Radioactivity was
measured using a scintillation counter (Tricarb 2100 TR, PerkinElmer,
AUS). The proportion of radiation relative to the total injectate is
shown. All radioactivity studies were performed in triplicate. For
analysis of NAD generation, following QD-NMN or NMN treatment
for 2 h, cells were washed with PBS and lysed with NAD extraction
buffer per NAD/NADH kit instructions. Samples were then prepared
as described in the assay section. Studies were performed in triplicate.
LSEC Fenestration Ultrastructure Imaging. The in vitro effects
of NMN andQD-NMNon fenestrations were evaluated using scanning
electron microscopy (SEM). SEM and analysis were performed as
previous described,17 using a JEOL 6380 scanning electron microscope
(JEOL Ltd., AUS). Images were collected at 10,000× magnification.
Image analysis was performed by a blinded observer using ImageJ
(NIH, USA). Between 1094 and 1272 fenestrations were counted per
treatment. Fenestrations less than 30 nm and gaps more than 300 nm
were excluded from the analysis. Porosity was defined as the percentage
of the cell membrane covered with fenestrations. Frequency was
defined as the number of fenestrations per 1 μm2.
Oral Glucose Tolerance Testing and Insulin Levels. oGTTs
were performed following a 4 h fast in young and old mice. Blood
glucose was measured used a hand-held glucometer using Accu-check
proforma strips. Blood was collected by tail vein sampling following a
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tail snip. Blood glucose was collected−15, 0, 15, 30, 45, 60, and 90 min
after an oral bolus of 2 g/kg glucose solution. Insulin was measured
using an ultrasensitive mouse insulin ELISA kit according to the
manufacturer’s instructions. Ten microliters of blood was collected
following a 4 h fast (−15 min) and after an oral bolus of 2 g/kg glucose
solution (15 min).
Administration of Drugs in DrinkingWater.Drinking water was
spiked with QD, QD-NMN, and NMN. Dosages were determined
based on the daily water intake and weight of the mice. Dosages used
were as follows: QD (250 μg/kg), QD-NMN (250 μg/kg and 8 mg/
kg), and NMN (800 mg/kg).
Histology and Immunofluorescence.The 4% paraformaldehyde
fixed samples were processed using a Tissue Tek VIP 6AI tissue
processor (Sakura Finetek, USA) and embedded in wax. Sections were
cut on a microtome and mounted on Superfrost slides. H&E and Sirius
Red staining were performed as previously described.70 Immuno-
fluorescence for TNFα (1:100) was performed following blocking and
conjugated with anti-rabbit secondary antibody. Nuclei were visualized
with Hoechst 33342. Imaging was performed on either a Leica SP8
(Leica Microsystems, AUS) or an EVOS FL Auto 2 (ThermoFisher,
AUS). Image preparation was performed using SlideBook software
(Leica Microsystems, AUS) and ImageJ software (NIH, USA).
Liver fibrosis was quantified based on METAVIR scoring:46,47 0, no
fibrosis; 1, mild fibrosis of the portal veins; 2, fibrotic septae between
portal veins; 3, fibrotic septae between portal and central vein; 4,
cirrhosis.
Autometallography Staining. Autometallography staining was
performed as previously described.71 In brief, glassware was cleaned for
48 h prior using Farmer solution (10% sodium thiosulfate, 10%
potassium ferricyanide); deparaffinized and hydrated sections were
incubated at for 90 min at 26 °C with autometallography developer
solution (1.2% carboxymethylcellulose, 9.2 mg/mL hydroquinone, 9
mg/mL silver lactate, in citrate buffer pH 3.8). Slides were washed with
5% sodium thiosulfate and counterstained with hematoxylin.
Inductively Coupled Plasma Mass Spectrometry. Seventy-five
milligram liver samples were collected from control (100-day toxicity
controls), 14 day (250 μg/kg/day), and 100 day (320 μg/kg/day) QD-
treated mice (n = 5 per group). Samples were dissolved in >90% nitric
acid at room temperature overnight. Solutions were diluted to 1% nitric
acid with MQ and centrifuged to remove precipitated protein, and
supernatants were collected for elemental analysis using ICP-MS
(NexION 2000, PerkinElmer, USA) fitted with a glass cyclonic spray
chamber. Multielement standard solution was used for calibration of
Ag, and Rh was used as internal standard. The dwell time for 103Rh
measurement was 50 and 500 ms for 107Ag, and 20 sweeps per reading,
one reading per replicate and three replicates were performed for each
sample. Detection limit for Ag was 0.054 ppt. Syngistix for ICP-MS
software was used for data collection and processing.
Statistics. All statistical analysis was performed using Kruskal−
Wallis tests with a post-hoc Dunn’s method (n = 3 experiments) or one-
way ANOVA with post-hoc Bonferroni test (n = 5 experiments); post-
hoc methods were applied for comparison between multiple groups
(GraphPad Prism 8.4.0, GraphPad Software, Inc., USA). Power
calculations were performed as previously described.72 All data
presented in Figure 1 are expressed as mean ± SD (n = 3); data in
Figures 2−8 are expressed in mean ± SD; Figures 2−5 are n = 3, and
Figures 6−8 are n = 5.
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